Skip to main content
Top
Published in: Critical Care 1/2006

01-02-2006 | Poster presentation

The erythropoietin neuroprotective effect: assessment in coronary artery bypass graft surgery (TENPEAKS) – a randomized, double-blind, placebo-controlled, proof-of-concept clinical trial

Authors: G Haljan, A Maitland, A Buchan, M King, J Haigh, B Culleton, P Faris, D Zygun

Published in: Critical Care | Special Issue 1/2006

Login to get access

Excerpt

Human recombinant erythropoietin (rh-Epo) may be a potent neuroprotectant [1]. It is approved in Canada to reduce blood transfusions in coronary artery bypass graft (CABG) surgery, which is complicated by neurocognitive dysfunction (NCD) in 50–80% of patients at discharge, 10–36% at 6 weeks and 42% at 5 years [2]. We conducted a randomized, double-blind, placebo-controlled study in 32 first-time CABG patients to investigate the feasibility and safety of three doses of rh-Epo with the ultimate goal of reducing NCD in patients following CABG. …
Metadata
Title
The erythropoietin neuroprotective effect: assessment in coronary artery bypass graft surgery (TENPEAKS) – a randomized, double-blind, placebo-controlled, proof-of-concept clinical trial
Authors
G Haljan
A Maitland
A Buchan
M King
J Haigh
B Culleton
P Faris
D Zygun
Publication date
01-02-2006
Publisher
BioMed Central
Published in
Critical Care / Issue Special Issue 1/2006
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc4574

Other articles of this Special Issue 1/2006

Critical Care 1/2006 Go to the issue